Grimes & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$403K Buy
770
+11
+1% +$5.63K 0.01% 343
2026
Q2
$377K Buy
759
+111
+17% +$49.2K 0.01% 347
2026
Q1
$289K Buy
648
+12
+2% +$5.6K 0.01% 365
2025
Q4
$288K Buy
636
+15
+2% +$6.46K 0.01% 388
2025
Q3
$243K Sell
621
-87
-12% -$36.4K 0.01% 404
2025
Q2
$315K Buy
708
+2
+0.3% +$922 0.01% 330
2025
Q1
$342K Buy
706
+57
+9% +$26.6K 0.01% 279
2024
Q4
$261K Buy
649
+19
+3% +$8.81K 0.01% 328
2024
Q3
$293K Buy
630
+1
+0.2% +$480 0.01% 293
2024
Q2
$295K Buy
629
+22
+4% +$9.5K 0.01% 273
2024
Q1
$254K Buy
607
+98
+19% +$41.4K 0.01% 290
2023
Q4
$207K Buy
+509
New +$188K 0.01% 301
2022
Q2
– Sell
-911
Closed -$238K – 301
2022
Q1
$238K Buy
+911
New +$216K 0.01% 265

Other funds holding VRTX

Grimes & Company's VRTX Position: Q3 2026 in Review

Grimes & Company increased its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q3 2026, buying an estimated $5.63K and bringing the position to 770 shares worth $403K. The position accounts for 0.01% of the portfolio, ranked #343.

Grimes & Company first reported a position in VRTX in Q1 2022 and has held it in 13 quarters since. 1,722 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Grimes & Company held 770 shares of Vertex Pharmaceuticals worth $403K as of Q3 2026.
  • Grimes & Company bought 11 Vertex Pharmaceuticals shares in Q3 2026, an estimated $5.63K.
  • Vertex Pharmaceuticals made up 0.01% of Grimes & Company's portfolio in Q3 2026, its #343 holding.
  • Grimes & Company first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • 1,722 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Grimes & Company's 13F filing for Q3 2026, filed 29 Oct 2026.